Followers | 29 |
Posts | 2446 |
Boards Moderated | 0 |
Alias Born | 11/22/2010 |
Monday, October 10, 2016 11:06:57 PM
I expect news within the month on data she's been analyzing with regards to this years Fast Field trials which were conducted on the Canadian Harvest. Just My Opinion!
09/28/2016
(GlobeNewswire) - Metabolix, Inc. (NASDAQ:MBLX), today announced that Heike Sederoff, Ph.D. Professor, Department of Plant and Microbial Biology at North Carolina State University (NC State) has been named to the Yield10 Bioscience Scientific Advisory Board (SAB). Yield10 Bioscience, the crop science venture launched by Metabolix in 2015, is focused on developing proprietary, breakthrough technologies to create step-changes in yield for major food and feed crops to enhance global food security.
We are pleased to welcome Dr. Sederoff to our Scientific Advisory Board, said Oliver Peoples, Ph.D., chief scientific officer. We have collaborated with Dr. Sederoff and her team at NC State on advanced metabolic engineering technologies for improving crop yield using camelina as a model system. We look forward to Heikes contributions in her role as an advisor to our team as we work in 2016 to translate our approach to boosting crop yield and drought resistance to agriculturally significant crops and move from greenhouse to field trials.
We have collaborated with the Yield10 team on grants supporting advanced research to improve seed and biomass yield in oilseed crops, said Heike Sederoff, Ph.D. Professor, Department of Plant and Microbial Biology at North Carolina State University. Our work focused on yield improvement using camelina has produced encouraging results and we look forward to continue working with the Yield10 team to engineer new plant yield traits applicable to important feed and food crops.
Heike Sederoff, Ph.D. is currently Professor in the Department of Plant and Molecular Biology and Systems and Synthetic Biology Chair at North Carolina State University. Dr. Sederoffs recent research has focused on the study of plant systems and synthetic biology. She has used metabolic engineering methods to increase carbon assimilation and allocation in an oilseed crop and in model plant species including marine algae. Dr. Sederoff received an M.S. in Biochemistry and a Ph.D. in Plant Biochemistry at University of Gttingen, Germany.
Earlier in 2016, Yield10 Bioscience named Michael Lassner, Ph.D., former vice president of trait discovery at Dupont Pioneer and Danny Schnell, Ph.D., Professor and Chair of the Department of Plant Biology at Michigan State University, to its SAB.
For more information, visit www.metabolix.com. (MBLX-G)
For more information on Yield10 Bioscience, visit Yield10.
Recent YTEN News
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/07/2024 08:01:17 PM
- Yield10 Bioscience Announces 1-for-24 Reverse Stock Split • GlobeNewswire Inc. • 05/01/2024 12:30:00 PM
- Yield10 Bioscience Announces Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 04/01/2024 08:01:07 PM
- Yield10 Bioscience to Announce Fourth Quarter and Full Year 2023 Financial Results and Host a Conference Call on Monday, April 1, 2024 • GlobeNewswire Inc. • 03/28/2024 08:01:20 PM
- Yield10 Bioscience Announces that the Plant Biosafety Office of the Canadian Food Inspection Agency has Cleared Genome-edited E3902 Camelina for Planting in Canada • GlobeNewswire Inc. • 03/26/2024 12:29:24 PM
- USDA-APHIS Determines that Yield10 Bioscience’s Omega-3 Camelina Varieties May Be Planted and Bred in the United States • GlobeNewswire Inc. • 03/21/2024 12:29:14 PM
- Yield10 Bioscience Reports that Proprietary Varieties of Winter Camelina Show Tolerance to Commonly Used Herbicides in First Field Tests • GlobeNewswire Inc. • 02/29/2024 01:31:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 09:37:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 03:09:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 11:29:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 11:26:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 11:25:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 05:45:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 04:34:18 PM
- Yield10 Bioscience Grants Global License to VISION Bioenergy Oilseeds for Herbicide Tolerant Camelina Cultivated for the Production of Biofuel Feedstock • GlobeNewswire Inc. • 02/14/2024 02:00:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 10:19:22 PM
- Yield10 Bioscience Provides an Update on its Omega-3 Camelina Program • GlobeNewswire Inc. • 02/07/2024 10:40:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 02:47:54 AM
- Yield10 Bioscience Files Request for Regulatory Status Review with USDA-APHIS for Camelina Designed to Produce the EPA and DHA Components of Omega-3 Oil • GlobeNewswire Inc. • 01/08/2024 01:31:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:35:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:29:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 09:11:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/17/2023 09:27:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 09:59:53 PM
- USDA-APHIS Determines that Yield10 Bioscience’s Stacked Herbicide Tolerant Camelina May Be Planted and Bred in the United States • GlobeNewswire Inc. • 11/15/2023 01:32:19 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM